Informed Consent Should Address Standard Of Care Risks, US FDA’s Califf Says

Information gaps still exist in informed consent documents, even though they are long and legalistic, FDA Commissioner Robert Califf said. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

More from R&D